ETF Holdings Breakdown of STOK

News associated with STOK

Legal & General Group Plc Has $390,000 Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Legal & General Group Plc trimmed its position in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,347 shares of the company’s stock after selling 2,139 shares during the quarter. Legal & General […] - 2025-05-01 07:42:53

Renaissance Technologies LLC Buys Shares of 129,043 Stoke Therapeutics, Inc. (NASDAQ:STOK)

Renaissance Technologies LLC purchased a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 129,043 shares of the company’s stock, valued at approximately $1,423,000. Other large investors have […] - 2025-04-29 07:58:53

Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $22.00 price objective on the stock. Needham & Company LLC’s price objective suggests a potential upside of 237.42% from […] - 2025-04-11 07:46:50

HC Wainwright Reaffirms “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $47.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 464.23% from the stock’s previous close. HC […] - 2025-03-21 06:25:10

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They presently have a $22.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 166.34% from the stock’s […] - 2025-03-20 06:44:48

Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Target Price at $23.00

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have earned an average rating of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy […] - 2025-02-28 06:26:56

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Target Price from Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has earned an average recommendation of “Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The […] - 2025-02-03 06:24:54

STOK institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	6,412	USD 58,029 4.3%
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	34,920	USD 316,026 4.3%
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	26,327	USD 238,259
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	26,327	USD 238,259 4.3%
Total =		93,986	USD 850,573

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer